Programmed death ligand 1 expression in bladder rhabdomyosarcoma and its association with clinicopathological features

Peng Zhou, Qiongren Wang, Chongshan Wang, Xiezhao Li, Wei Du, Chunxiao Liu, Masami Watanabe, Peng Huang, Abai Xu

Research output: Contribution to journalArticle

Abstract

The aim of this study was to detect PD-L1 expression in bladder rhabdomyosarcoma and its association with clinicopathological features and patient prognosis. PD-L1 expression was detected in paraffin-embedded sections obtained from 34 patients with bladder rhabdomyosarcoma via immunohistochemistry. Immunohistochemistry results were statistically analyzed to determine their association with patient clinicopathological features and survival outcomes. PD-L1-positive staining was observed in 47.1% (16/34) of patients. Metastatic tumor cells in the lymph nodes of two patients were positive for PD-L1 expression. PD-L1 expression was significantly different with regard to muscularis invasion, but the expression did not affect patient survival outcomes. We confirmed PD-L1 expression in bladder rhabdomyosarcoma, suggesting that PD-1/PD-L1 inhibitors are potential therapeutic agents for patients with bladder rhabdomyosarcoma.

Original languageEnglish
Pages (from-to)10565-10570
Number of pages6
JournalInternational Journal of Clinical and Experimental Pathology
Volume10
Issue number10
Publication statusPublished - 2017

Keywords

  • Expression
  • Overall survival
  • Programmed death ligand 1
  • Rhabdomyosarcoma
  • Urinary bladder

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology

Fingerprint Dive into the research topics of 'Programmed death ligand 1 expression in bladder rhabdomyosarcoma and its association with clinicopathological features'. Together they form a unique fingerprint.

  • Cite this